Reported 11 months ago
Eli Lilly is experiencing success with its diabetes and weight-loss treatments Mounjaro and Zepbound, with expected revenues of $13.5 billion in 2024. Despite the positive outlook, there are criticisms about pricing and access, especially regarding the nearly $1,000 list price for their GLP-1 drugs. While Lilly brought Zepbound to the market at a discount, access issues persist, particularly for Medicare beneficiaries. The company is focusing on innovation and addressing different diseases with its drugs while being aware of the need for continued progress in obesity treatment.
Source: YAHOO